Drug Approval

Advertisement
Blog Post

FDA Approves Reata’s SKYCLARYS for Treatment of FA

By Sujatha Gurunathan | February 28, 2023
Blog Post

MDA Celebrates the Approval of Relyvrio from Amylyx for the Treatment of ALS

By MDA Staff | September 30, 2022
RADICAVA ORS
Blog Post

FDA Approves MTPA’s RADICAVA ORS for Treatment of ALS

By Sujatha Gurunathan | May 13, 2022
Scientific conference speakers
Featured Article

A Successful In-Person Conference

By MDA Staff | May 13, 2022

FDA Approves Alexion’s Ultomiris for Treatment of gMG

By Sujatha Gurunathan | April 28, 2022
dystrophin
Blog Post

Simply Stated: What is Duchenne Muscular Dystrophy?

By Sujatha Gurunathan | February 16, 2022
Blog Post

FDA Approves argenx’s Vyvgart for Treatment of gMG

By Sujatha Gurunathan | December 20, 2021
Featured Article

Demystifying Drug Prices

By Larry Luxner | November 19, 2021
Blog Post

FDA Approves Sanofi Genzyme’s Nexviazyme for Treatment of Pompe Disease

By MDA Staff | August 6, 2021
Blog Post

FDA approves Octapharma’s Octagam® 10% for Treatment of Adults with Dermatomyositis

By Sujatha Gurunathan | July 29, 2021